Granules India Climbs 2% as US Unit Bags Clean USFDA Inspection Nod
Shares of Granules India Limited touched a day high of Rs 797.00 on 3 June after the company disclosed that its wholly owned US subsidiary, Granules Pharmaceuticals Inc. (GPI), received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration for its Chantilly, Virginia facility.
The USFDA classified the inspection outcome as Voluntary Action Indicated (VAI). That means the regulator found some observations during the visit but closed the inspection without taking any regulatory action.
No restrictions, no enforcement, the facility continues to operate normally.
The inspection ran from 30 March to 3 April 2026, during which four observations were recorded in Form 483. Granules India told exchanges that the Chantilly facility is central to its global manufacturing and supply network, with a focus on quality systems, regulatory compliance and patient safety.
This is not an isolated result. Back in early April, shares had also rallied around 2% after Granules Life Sciences received a VAI classification for its Shamirpet, Telangana plant.
Before that, Granules Consumer Health LLC, a step-down subsidiary of GPI, got a No Action Indicated (NAI) status for its Manassas, Virginia packaging facility in March.
Three positive USFDA inspection outcomes across different facilities in quick succession.
At 15:15 pm on NSE, GRANULES was trading at Rs 793.60, up 2.06% from its previous close of Rs 777.55. The stock has gained over 28% so far in 2026.
Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!
